<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; equivalent</title>
	<atom:link href="http://www.tapanray.in/tag/equivalent/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Does India need an equivalent of ‘The Physician Payment Sunshine Act’ of the US for transparency in pharmaceutical marketing?</title>
		<link>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing</link>
		<comments>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/#comments</comments>
		<pubDate>Mon, 14 Nov 2011 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[equivalent]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=175</guid>
		<description><![CDATA[Currently a strong and palpable public sentiment against corruption has engulfed India albeit more than what we witness in movements like &#8216;Occupy Wall Street&#8217; against systemic corruption not only in the US but in a large number of cities across &#8230; <a href="http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-need-an-equivalent-of-the-physician-payment-sunshine-act-of-the-us-for-transparency-in-pharmaceutical-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>85% of the patented new drugs have therapeutic equivalents…they do not increase the cost of treatment for the common man: Points…Counterpoints</title>
		<link>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints</link>
		<comments>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/#comments</comments>
		<pubDate>Mon, 21 Jun 2010 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[85%]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterpoints]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[equivalent]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Have]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[man]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=412</guid>
		<description><![CDATA[Affordability of patented drugs has become a major controversial and at the same time a very sensitive issue in the healthcare space of India, just as in many other parts of the world. The government, the NGOs and other stakeholders, &#8230; <a href="http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/85-of-the-patented-new-drugs-have-therapeutic-equivalentsthey-do-not-increase-the-cost-of-treatment-for-the-common-man-pointscounterpoints/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
